z-logo
Premium
Determination of the concentration of gilteritinib in human plasma using HPLC
Author(s) -
Yasu Takeo,
Sugi Tomiyuki,
Momo Kenji,
Hagihara Masao,
Yasui Hiroshi
Publication year - 2021
Publication title -
biomedical chromatography
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.4
H-Index - 65
eISSN - 1099-0801
pISSN - 0269-3879
DOI - 10.1002/bmc.5028
Subject(s) - chemistry , chromatography , calibration curve , high performance liquid chromatography , extraction (chemistry) , protein precipitation , detection limit
Gilteritinib, an oral inhibitor of FMS‐like tyrosine kinase 3 (FLT3), is a standard treatment for FLT3‐mutated acute myeloid leukemia. We developed a simple HPLC‐UV‐based method for determining the concentration of gilteritinib in human plasma. The analysis requires the extraction of a 200‐μL plasma sample and the precipitation of proteins by solid‐phase extraction. Gilteritinib was isocratically separated within 10 min using a mobile phase of acetonitrile:0.5% monopotassium phosphate (KH 2 PO 4 , pH 3.5, 28:72, v/v) on a Capcell Pack C18 MG II (250 × 4.6 mm) column at a flow rate of 1.0 mL/min and monitored at 250 nm. The calibration curve was found to be linear within a plasma concentration range of 25–2500 ng/mL, with the coefficient of determination ( r 2 ) being 0.9997. The coefficients of intra‐day and inter‐day validation were 2.3–3.7 and 1.3–5.2%, respectively. The accuracy and recovery of the assay were −9.6 to 0.1 and >81.8%, respectively. This HPLC‐UV method for determining the plasma concentration of gilteritinib is simple and can be effectively applied to routine drug monitoring.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here